Proton pump inhibitors and gastritis

Masayuki Suzuki, Hidekazu Suzuki, Toshifumi Hibi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Summary Proton pump inhibitors (PPIs) are novel compounds that strongly inhibit the H+/K+-ATPase in the gastric parietal cells to cause profound suppression of acid secretion. Acid-generating ATPase, also known as vacuolar-type ATPase, is located in the lysozomes of leukocytes and osteoclasts and its activity is also reportedly influenced by treatment with PPIs. This concept is supported by the results of studies using autoradiography in which 3H-Lansoprazole uptake sites were clearly detected in the cytoplasmic granules of neutrophils infiltrating the gastric mucosa. In vitro studies indicate that PPIs increase the intra-vacuolar pH in the lysosomes of purified neutrophils and attenuate the adherence of neutrophils to the vascular endothelium. In clinical practice, the acidic environment in the stomach plays a critical role in the development of gastritis induced by Helicobacter pylori {H. pylori). This is worthy of note, because persistent gastritis often results in atrophic and metaplastic changes in the gastric mucosa, which are believed to be preneoplastic abnormalities. In patients with H. pylori-infection, PPI therapy causes corpus-predominant gastritis, which is frequently found in the background mucosa in patients with gastric cancer. The efficacy and safety of long-term PPI-treatment have not been conclusive, thus we need to pay more attention to the additional pharmacological actions of PPIs.

Original languageEnglish
Pages (from-to)71-75
Number of pages5
JournalJournal of Clinical Biochemistry and Nutrition
Volume42
Issue number2
DOIs
Publication statusPublished - 2008 Mar

Fingerprint

gastritis
Proton Pump Inhibitors
Gastritis
neutrophils
Neutrophils
Helicobacter pylori
gastric mucosa
Gastric Mucosa
adenosinetriphosphatase
Adenosine Triphosphatases
stomach
Gastric Parietal Cells
Lansoprazole
Vacuolar Proton-Translocating ATPases
cytoplasmic granules
Cytoplasmic Granules
osteoclasts
Acids
Proton-Translocating ATPases
stomach neoplasms

Keywords

  • Gastritis
  • Helicobacter pylori
  • Leukocyte
  • Osteoclast
  • Vacuolar H-ATPase

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

Proton pump inhibitors and gastritis. / Suzuki, Masayuki; Suzuki, Hidekazu; Hibi, Toshifumi.

In: Journal of Clinical Biochemistry and Nutrition, Vol. 42, No. 2, 03.2008, p. 71-75.

Research output: Contribution to journalArticle

Suzuki, Masayuki ; Suzuki, Hidekazu ; Hibi, Toshifumi. / Proton pump inhibitors and gastritis. In: Journal of Clinical Biochemistry and Nutrition. 2008 ; Vol. 42, No. 2. pp. 71-75.
@article{2f313b784bfe40a0acba4b6202a2bbec,
title = "Proton pump inhibitors and gastritis",
abstract = "Summary Proton pump inhibitors (PPIs) are novel compounds that strongly inhibit the H+/K+-ATPase in the gastric parietal cells to cause profound suppression of acid secretion. Acid-generating ATPase, also known as vacuolar-type ATPase, is located in the lysozomes of leukocytes and osteoclasts and its activity is also reportedly influenced by treatment with PPIs. This concept is supported by the results of studies using autoradiography in which 3H-Lansoprazole uptake sites were clearly detected in the cytoplasmic granules of neutrophils infiltrating the gastric mucosa. In vitro studies indicate that PPIs increase the intra-vacuolar pH in the lysosomes of purified neutrophils and attenuate the adherence of neutrophils to the vascular endothelium. In clinical practice, the acidic environment in the stomach plays a critical role in the development of gastritis induced by Helicobacter pylori {H. pylori). This is worthy of note, because persistent gastritis often results in atrophic and metaplastic changes in the gastric mucosa, which are believed to be preneoplastic abnormalities. In patients with H. pylori-infection, PPI therapy causes corpus-predominant gastritis, which is frequently found in the background mucosa in patients with gastric cancer. The efficacy and safety of long-term PPI-treatment have not been conclusive, thus we need to pay more attention to the additional pharmacological actions of PPIs.",
keywords = "Gastritis, Helicobacter pylori, Leukocyte, Osteoclast, Vacuolar H-ATPase",
author = "Masayuki Suzuki and Hidekazu Suzuki and Toshifumi Hibi",
year = "2008",
month = "3",
doi = "10.3164/jcbn.2008012",
language = "English",
volume = "42",
pages = "71--75",
journal = "Journal of Clinical Biochemistry and Nutrition",
issn = "0912-0009",
publisher = "The Society for Free Radical Research Japan",
number = "2",

}

TY - JOUR

T1 - Proton pump inhibitors and gastritis

AU - Suzuki, Masayuki

AU - Suzuki, Hidekazu

AU - Hibi, Toshifumi

PY - 2008/3

Y1 - 2008/3

N2 - Summary Proton pump inhibitors (PPIs) are novel compounds that strongly inhibit the H+/K+-ATPase in the gastric parietal cells to cause profound suppression of acid secretion. Acid-generating ATPase, also known as vacuolar-type ATPase, is located in the lysozomes of leukocytes and osteoclasts and its activity is also reportedly influenced by treatment with PPIs. This concept is supported by the results of studies using autoradiography in which 3H-Lansoprazole uptake sites were clearly detected in the cytoplasmic granules of neutrophils infiltrating the gastric mucosa. In vitro studies indicate that PPIs increase the intra-vacuolar pH in the lysosomes of purified neutrophils and attenuate the adherence of neutrophils to the vascular endothelium. In clinical practice, the acidic environment in the stomach plays a critical role in the development of gastritis induced by Helicobacter pylori {H. pylori). This is worthy of note, because persistent gastritis often results in atrophic and metaplastic changes in the gastric mucosa, which are believed to be preneoplastic abnormalities. In patients with H. pylori-infection, PPI therapy causes corpus-predominant gastritis, which is frequently found in the background mucosa in patients with gastric cancer. The efficacy and safety of long-term PPI-treatment have not been conclusive, thus we need to pay more attention to the additional pharmacological actions of PPIs.

AB - Summary Proton pump inhibitors (PPIs) are novel compounds that strongly inhibit the H+/K+-ATPase in the gastric parietal cells to cause profound suppression of acid secretion. Acid-generating ATPase, also known as vacuolar-type ATPase, is located in the lysozomes of leukocytes and osteoclasts and its activity is also reportedly influenced by treatment with PPIs. This concept is supported by the results of studies using autoradiography in which 3H-Lansoprazole uptake sites were clearly detected in the cytoplasmic granules of neutrophils infiltrating the gastric mucosa. In vitro studies indicate that PPIs increase the intra-vacuolar pH in the lysosomes of purified neutrophils and attenuate the adherence of neutrophils to the vascular endothelium. In clinical practice, the acidic environment in the stomach plays a critical role in the development of gastritis induced by Helicobacter pylori {H. pylori). This is worthy of note, because persistent gastritis often results in atrophic and metaplastic changes in the gastric mucosa, which are believed to be preneoplastic abnormalities. In patients with H. pylori-infection, PPI therapy causes corpus-predominant gastritis, which is frequently found in the background mucosa in patients with gastric cancer. The efficacy and safety of long-term PPI-treatment have not been conclusive, thus we need to pay more attention to the additional pharmacological actions of PPIs.

KW - Gastritis

KW - Helicobacter pylori

KW - Leukocyte

KW - Osteoclast

KW - Vacuolar H-ATPase

UR - http://www.scopus.com/inward/record.url?scp=46249129416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249129416&partnerID=8YFLogxK

U2 - 10.3164/jcbn.2008012

DO - 10.3164/jcbn.2008012

M3 - Article

C2 - 18385822

AN - SCOPUS:46249129416

VL - 42

SP - 71

EP - 75

JO - Journal of Clinical Biochemistry and Nutrition

JF - Journal of Clinical Biochemistry and Nutrition

SN - 0912-0009

IS - 2

ER -